|
Schizophrenia
|
0.350 |
Biomarker
|
disease |
BEFREE |
HDAC1 links early life stress to schizophrenia-like phenotypes.
|
28533418 |
2018 |
|
Schizophrenia
|
0.350 |
AlteredExpression
|
disease |
BEFREE |
Expression of HDAC2 but Not HDAC1 Transcript Is Reduced in Dorsolateral Prefrontal Cortex of Patients with Schizophrenia.
|
27959513 |
2017 |
|
Schizophrenia
|
0.350 |
Biomarker
|
disease |
BEFREE |
Toward dissecting the etiology of schizophrenia: HDAC1 and DAXX regulate GAD67 expression in an in vitro hippocampal GABA neuron model.
|
26812044 |
2016 |
|
Schizophrenia
|
0.350 |
Biomarker
|
disease |
PSYGENET |
Postmortem brain studies have shown that HDAC1-a lysine deacetylase with broad activity against histones and nonhistone proteins-is frequently expressed at increased levels in prefrontal cortex (PFC) of subjects diagnosed with schizophrenia and related disease.
|
23664640 |
2014 |
|
Schizophrenia
|
0.350 |
AlteredExpression
|
disease |
BEFREE |
In summary, we suggest that reduced p35 expression in schizophrenia has an impact on synaptic protein expression and cognition and that these deficits can be rescued, at least in part, by the inhibition of histone deacetylase 1.
|
21772061 |
2011 |
|
Schizophrenia
|
0.350 |
AlteredExpression
|
disease |
LHGDN |
The mRNA expression level of an epigenetically regulated schizophrenia candidate gene GAD67 was strongly and negatively correlated with the mRNA expression levels of HDAC1, HDAC3 and HDAC4 levels.
|
17961987 |
2008 |
|
Schizophrenia
|
0.350 |
AlteredExpression
|
disease |
BEFREE |
The mRNA expression level of an epigenetically regulated schizophrenia candidate gene GAD67 was strongly and negatively correlated with the mRNA expression levels of HDAC1, HDAC3 and HDAC4 levels.
|
17961987 |
2008 |
|
Schizophrenia
|
0.350 |
Biomarker
|
disease |
PSYGENET |
HDAC1 expression levels were significantly higher in schizophrenia versus normal subjects.
|
17961987 |
2008 |
|
Squamous cell carcinoma
|
0.330 |
AlteredExpression
|
disease |
BEFREE |
In this study, we show that vorinostat (2 μM) reduced expression of HDAC1, 2, 3, and 7 in epidermoid carcinoma A431 cells.
|
23147569 |
2013 |
|
Squamous cell carcinoma
|
0.330 |
Biomarker
|
disease |
CTD_human |
Physical association of HDAC1 and HDAC2 with p63 mediates transcriptional repression and tumor maintenance in squamous cell carcinoma.
|
21527555 |
2011 |
|
Squamous cell carcinoma
|
0.330 |
AlteredExpression
|
disease |
BEFREE |
Physical association of HDAC1 and HDAC2 with p63 mediates transcriptional repression and tumor maintenance in squamous cell carcinoma.
|
21527555 |
2011 |
|
Squamous cell carcinoma
|
0.330 |
AlteredExpression
|
disease |
LHGDN |
histone deacetylase 1 overexpression is associated with advanced stage esophageal squamous cell carcinoma.
|
12579268 |
2003 |
|
Endometrioma
|
0.310 |
AlteredExpression
|
disease |
BEFREE |
Histone deacetylase-1 target mRNAs that were up-regulated by valproic acid (VPA) treatment in endometriotic cyst stromal cells (ECSCs) were identified by a global mRNA microarray technique.
|
23833041 |
2013 |
|
Endometriosis
|
0.310 |
AlteredExpression
|
disease |
BEFREE |
HDAC1 and HDAC2 are differentially expressed in endometriosis.
|
22344732 |
2012 |
|
Endometriosis
|
0.310 |
Biomarker
|
disease |
CTD_human |
Nuclear receptor, coregulator signaling, and chromatin remodeling pathways suggest involvement of the epigenome in the steroid hormone response of endometrium and abnormalities in endometriosis.
|
22138541 |
2012 |
|
Endometrioma
|
0.310 |
Biomarker
|
disease |
CTD_human |
Nuclear receptor, coregulator signaling, and chromatin remodeling pathways suggest involvement of the epigenome in the steroid hormone response of endometrium and abnormalities in endometriosis.
|
22138541 |
2012 |
|
Mood Disorders
|
0.300 |
Biomarker
|
group |
PSYGENET |
These results provide evidence that selective inhibition of HDAC1 and HDAC2 in brain may provide an epigenetic-based target for developing improved treatments for mood disorders and other brain disorders with altered chromatin-mediated neuroplasticity.
|
23967191 |
2014 |
|
Familial primary pulmonary hypertension
|
0.300 |
Biomarker
|
disease |
CTD_human |
Histone deacetylation inhibition in pulmonary hypertension: therapeutic potential of valproic acid and suberoylanilide hydroxamic acid.
|
22711276 |
2012 |
|
PULMONARY HYPERTENSION, PRIMARY, DEXFENFLURAMINE-ASSOCIATED
|
0.300 |
Biomarker
|
disease |
CTD_human |
Histone deacetylation inhibition in pulmonary hypertension: therapeutic potential of valproic acid and suberoylanilide hydroxamic acid.
|
22711276 |
2012 |
|
Pulmonary Hypertension, Primary, Fenfluramine-Associated
|
0.300 |
Biomarker
|
disease |
CTD_human |
Histone deacetylation inhibition in pulmonary hypertension: therapeutic potential of valproic acid and suberoylanilide hydroxamic acid.
|
22711276 |
2012 |
|
Idiopathic pulmonary arterial hypertension
|
0.300 |
Biomarker
|
disease |
CTD_human |
HDAC1 and HDAC5 protein levels were elevated in lungs from human idiopathic pulmonary arterial hypertension and in lungs and right ventricles from rats exposed to hypoxia.
|
22711276 |
2012 |
|
Pulmonary Hypertension, Primary, 1, With Hereditary Hemorrhagic Telangiectasia
|
0.300 |
Biomarker
|
disease |
CTD_human |
Histone deacetylation inhibition in pulmonary hypertension: therapeutic potential of valproic acid and suberoylanilide hydroxamic acid.
|
22711276 |
2012 |
|
Heart Diseases
|
0.300 |
Biomarker
|
group |
CTD_human |
Transgenic overexpression of Hdac3 in the heart produces increased postnatal cardiac myocyte proliferation but does not induce hypertrophy.
|
18625706 |
2008 |
|
Pulmonary Hypertension
|
0.200 |
Biomarker
|
phenotype |
RGD |
Histone deacetylation inhibition in pulmonary hypertension: therapeutic potential of valproic acid and suberoylanilide hydroxamic acid.
|
22711276 |
2012 |
|
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
YY1 promotes HDAC1 expression and decreases sensitivity of hepatocellular carcinoma cells to HDAC inhibitor.
|
28489564 |
2018 |